Table of Contents
Chinese Journal of Biology
Volume 2015, Article ID 542542, 7 pages
http://dx.doi.org/10.1155/2015/542542
Research Article

Neuroprotective Effect of Juniperus communis on Chlorpromazine Induced Parkinson Disease in Animal Model

1Department of Pharmacology, Rayat Institute of Pharmacy, Railmajra, Shaheed Bhagat Singh Nagar, Punjab 144533, India
2Department of Pharmaceutical Chemistry, Rayat Institute of Pharmacy, Railmajra, Shaheed Bhagat Singh Nagar, Punjab 144533, India

Received 28 September 2014; Revised 8 January 2015; Accepted 26 January 2015

Academic Editor: Qiusheng Zheng

Copyright © 2015 Souravh Bais et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. L. Leenders and W. H. Oertel, “Parkinson's disease: clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions,” Neural Plasticity, vol. 8, no. 1-2, pp. 99–110, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Braak, U. Rüb, W. P. Gai, and K. Del Tredici, “Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen,” Journal of Neural Transmission, vol. 110, no. 5, pp. 517–536, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. A. M. Karch, Focus on Nursing Pharmacology, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 5th edition, 2009.
  4. S. Nikam, P. Nikam, S. K. Ahaley, and A. V. Sontakke, “Oxidative stress in Parkinson's disease,” Indian Journal of Clinical Biochemistry, vol. 24, no. 1, pp. 98–101, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. J. Clifton, L. K. Ward, and D. S. Ranner, “The status of juniper Juniperus communis L. In North-East England,” Biological Conservation, vol. 79, no. 1, pp. 67–77, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Kailash, B. G. Chaudhari, B. P. Dhar et al., Database on Medicinal Plants Used in Ayurveda, vol. 8, Central Council for Research in Ayurveda & Siddha, 2007.
  7. S. Bais, N. S. Gill, N. Rana, and S. Shandil, “A phytopharmacological review on a medicinal plant: Juniperus communis,” International Scholarly Research Notices, vol. 2014, Article ID 634723, 6 pages, 2014. View at Publisher · View at Google Scholar
  8. M. Hoferl, I. Stoilova, E. Schmidt et al., “Chemical composition and antioxidant properties of juniper berry (Juniperus communis L.) essential oil. Action of the essential oil on the antioxidant protection of Saccharomyces cerevisiae model organism,” Antioxidants, vol. 3, no. 1, pp. 81–98, 2014. View at Publisher · View at Google Scholar
  9. C. P. Khare, Indian Medicinal Plants, Springer, New York, NY, USA, 2007.
  10. S. Banerjee, A. Mukherjee, and T. K. Chatterjee, “Evaluation of analgesic activities of methanolic extract of medicinal plant Juniperus communis linn,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, no. 5, pp. 547–550, 2012. View at Google Scholar · View at Scopus
  11. S. C. Sati and S. Joshi, “Antibacterial potential of leaf extracts of Juniperus communis L. from Kumaun Himalaya,” African Journal of Microbiology Research, vol. 4, no. 12, pp. 1291–1294, 2010. View at Google Scholar · View at Scopus
  12. G. G. P. Manvi, “Screening and evaluation of pharmacognostic, phytochemical and hepatoprotective activity of linn stems,” International Journal of Pharma and Bio Sciences, vol. 1, no. 3, 2010. View at Google Scholar
  13. M. Akdogan, A. Koyu, M. Ciris, and K. Yildiz, “Anti-hypercholesterolemic activity of Oil in rats: a biochemical and histopathological investigation,” Biomedical Research, vol. 23, no. 3, pp. 321–328, 2012. View at Google Scholar
  14. H. Tunón, C. Olavsdotter, and L. Bohlin, “Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis,” Journal of Ethnopharmacology, vol. 48, no. 2, pp. 61–76, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Banerjee, H. Singh, and T. K. Chatterjee, “Evaluation of anti-diabetic and anti-hyperlipidemic potential of methanolic extract of Juniperus Communis (L.) in Streptozotocin-Nicotinamide induced diabetic rats,” International Journal of Pharma and Bio Sciences, vol. 4, no. 3, pp. P10–P17, 2013. View at Google Scholar · View at Scopus
  16. S. Bais, N. S. Gill, and N. Rana, “Effect of Juniperus communis extract on reserpine induced catalepsy,” Inventi Rapid: Ethnopharmacology, vol. 2014, no. 4, pp. 117–120, 2014. View at Google Scholar
  17. S. Pepeljnjak, I. Kosalec, Z. Kalodera, and N. Blažević, “Antimicrobial activity of juniper berry essential oil (Juniperus communis L., Cupressaceae),” Acta Pharmaceutica, vol. 55, no. 4, pp. 417–422, 2005. View at Google Scholar · View at Scopus
  18. L. Chen, Y. Ding, B. Cagniard et al., “Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice,” Journal of Neuroscience, vol. 28, no. 2, pp. 425–433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. C. K. Kokate, Practical Pharmacognosy, Vallabh Prakashan, 2005.
  20. K. R. Khandelwal, Practical Pharmacognosy Techniques and Experiments, 11th edition, 2004.
  21. G. E. Trease and W. C. Evans, Pharmacognosy, Bailliere Tindall, London, UK, 11th edition, 1989.
  22. OECD/OCDE 423 Annex 2, “Procedure to be followed for each of the starting doses,” in OECD Guideline For Testing of Chemicals, Acute Oral Toxicity-Acute Toxic Class Method, pp. 1/14–14/14, 2001. View at Google Scholar
  23. D. J. Ecobichnon, The Basis of Toxicity Testing, CRC Press, New York, NY, USA, 2nd edition, 1997.
  24. B. Costall and R. J. Naylor, “On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity,” Psychopharmacologia, vol. 34, no. 3, pp. 233–241, 1974. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Bishnoi, K. Chopra, and S. K. Kulkarni, “Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes,” European Journal of Pharmacology, vol. 552, no. 1–3, pp. 55–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. S. K. Kulkarni, Handbook of Experimental Pharmacology, Vallabh Prakashan, New Delhi, India, 2008.
  27. H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979. View at Publisher · View at Google Scholar · View at Scopus
  28. M. S. Moron, J. W. Depierre, and B. Mannervik, “Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver,” Biochimica et Biophysica Acta, vol. 582, no. 1, pp. 67–78, 1979. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Lidija, S. Vesna, J. Branka, and T. L. Dajana, “Effect of glutamate antagonists on nitric oxide production in rat brain following intrahippocampal injection,” Archives of Biological Sciences, vol. 59, no. 1, pp. 29–36, 2007. View at Google Scholar
  30. O. H. Lowry, N. J. Rosenbrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar · View at Scopus
  31. C. W. Olanow and W. G. Tatton, “Etiology and pathogenesis of Parkinson's disease,” Annual Review of Neuroscience, vol. 22, pp. 123–144, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. World Health Organization (WHO), Essential Medicines, WHO Model List, 13th edition, 2007.
  33. World Health Organization, Management of Substance Abuses the Bare Facts, WHO, 2010.
  34. A. Pillai, A. V. Terry Jr., and S. P. Mahadik, “Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus,” Schizophrenia Research, vol. 82, no. 1, pp. 95–106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. J. M. Pierre, “Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management,” Drug Safety, vol. 28, no. 3, pp. 191–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. H. R. Greenberg, “Inhibition of ejaculation by chlorpromazine.,” Journal of Nervous and Mental Disease, vol. 152, no. 5, pp. 364–366, 1971. View at Publisher · View at Google Scholar · View at Scopus
  37. R. M. Allen, “Dopamine hypersensitivity and tardive dyskinesia.,” The American Journal of Psychiatry, vol. 134, no. 10, pp. 1154–1155, 1977. View at Publisher · View at Google Scholar · View at Scopus
  38. S. K. Kulkarni, Handbook of Experimental Pharmacology, Vallabh Prakashan, New York, NY, USA, 3rd edition, 1999.
  39. D. T. Dexter, A. E. Holley, W. D. Flitter et al., “Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: an HPLC and ESR study,” Movement Disorders, vol. 9, no. 1, pp. 92–97, 1994. View at Publisher · View at Google Scholar · View at Scopus
  40. V. Parikh, M. M. Khan, and S. P. Mahadik, “Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain,” Journal of Psychiatric Research, vol. 37, no. 1, pp. 43–51, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. K. D. Tripathi, Essentials of Medical Pharmacology, Jaypee Brothers Medical Publishers, 6th edition, 2008.
  42. K. S. Sandhu and A. C. Rana, “Evaluation of anti parkinson’s activity of Nigella sativa (kalonji) seeds in chlorpromazine induced experimental animal model,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 5, p. 3, 2013. View at Google Scholar
  43. K. J. Barnham, C. L. Masters, and A. I. Bush, “Neurodegenerative diseases and oxidative stress,” Nature Reviews Drug Discovery, vol. 3, no. 3, pp. 205–214, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Nikolova, “Oxidative stress and Parkinson disease,” Trakia Journal of Sciences, vol. 10, no. 1, pp. 171–172, 2012. View at Google Scholar
  45. I. Guevara, J. Iwanejko, A. Dembińska-Kieć et al., “Determination of nitrite/nitrate in human biological material by the simple Griess reaction,” Clinica Chimica Acta, vol. 274, no. 2, pp. 177–188, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. V. L. Dawson, T. M. Dawson, D. A. Bartley, G. R. Uhl, and S. H. Snyder, “Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures,” The Journal of Neuroscience, vol. 13, no. 6, pp. 2651–2661, 1993. View at Google Scholar · View at Scopus